Skip to main content
. 2013 Feb 4;31(9):1172–1181. doi: 10.1200/JCO.2012.44.3184

Fig 1.

Fig 1.

Overview of research design and work flow. (A) Identification and validation of 24-gene signature; (B) development and validation of integrated risk classification scheme. AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CALGB, Cancer and Leukemia Group B; EFS, event-free survival; ELN, European LeukemiaNet; FDR, false discovery rate; HOVON, Hemato-Oncologie voor Volwassenen Nederland; OS, overall survival.